Raf1 Kinase Inhibitor I

A potent, cell-permeable, reversible, and ATP-competitive cRAF1 kinase inhibitor (IC₅₀ = 9 nM). Shows ≥100-fold selectivity for Raf kinase versus Cdk1, Cdk2, c-Src, ERK2, MEK, p38, Tie2, VEGFR2, and c-Fms. Predicted broad spectrum antitumor agents. A 10 mM (500 µg/96 µl) solution of Raf1 Inhibitor I (Cat. No. 553003) in DMSO is also available.

A potent, cell-permeable, reversible, and ATP-competitive cRaf1 kinase inhibitor (IC₅₀ = 9 nM). Shows ≥100-fold selectivity for Raf kinase versus Cdk1, Cdk2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms. cRaf1 inhibitors are predicted to be broad spectrum antitumor agents.

Cell permeable: yes

Primary Target
CRAFI kinase

Product competes with ATP.

Reversible: yes

Packaged under inert gas

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.







From Catalog:

Desc. Field- added "Predicted broad spectrum antitumor agents."

Lackey, K., et al. 2000. Bioorg. Med. Chem. Lett.10, 223.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany